Abstract
BACKGROUND
Breast cancer is one of the most common malignant tumors in women worldwide and poses a severe threat to their health. Therefore, this study examined patients who underwent breast cancer surgery, analyzed hospitalization costs and structure, and explored the impact of China Healthcare Security Diagnosis Related Groups (CHS-DRG) management on patient costs. It aimed to provide medical institutions with ways to reduce costs, optimize cost structures, reduce patient burden, and improve service efficiency.
AIM
To study the CHS-DRG payment system’s impact on breast cancer surgery costs.
METHODS
Using the CHS-DRG (version 1.1) grouping criteria, 4073 patients, who underwent the radical resection of breast malignant tumors from January to December 2023, were included in the JA29 group; 1028 patients were part of the CHS-DRG payment system, unlike the rest. Through an independent sample t-test, the length of hospital stay as well as total hospitalization, medicine and consumables, medical, nursing, medical technology, and management expenses were compared. Pearson’s correlation coefficient was used to test the cost correlation.
RESULTS
In terms of hospitalization expenses, patients in the CHS-DRG payment group had lower medical, nursing, and management expenses than those in the diagnosis-related group (DRG) non-payment group. For patients in the DRG payment group, the factors affecting the total hospitalization cost, in descending order of relevance, were medicine and consumable costs, consumable costs, medicine costs, medical costs, medical technology costs, management costs, nursing costs, and length of hospital stay. For patients in the DRG non-payment group, the factors affecting the total hospitalization expenses in descending order of relevance were medicines and consumable expenses, consumable expenses, medical technology expenses, the cost of medicines, medical expenses, nursing expenses, length of hospital stay, and management expenses.
CONCLUSION
The CHS-DRG system can help control and reduce unnecessary medical expenses by controlling medicine costs, medical consumable costs, and the length of hospital stay while ensuring medical safety.
Publisher
Baishideng Publishing Group Inc.
Reference11 articles.
1. Performance evaluation of medical service for breast cancer patients based on diagnosis related groups
2. National Healthcare Security Administration. Notice on issuing a list of national pilot cities for group payment based on disease diagnosis (YiBao Fa [2019] No. 34). Jun 5, 2019. [cited 24 March 2024]. Available from: http://www.nhsa.gov.cn/art/2019/6/5/art_37_1362.html
3. National Healthcare Security Administration. Notice on issuing the three-year action plan for DRG/DIP payment method reform (YiBao Fa [2021] No. 48). Nov 26, 2021. [cited 24 March 2024]. Available from: http://www.nhsa.gov.cn/art/2021/11/26/art_104_7413.html
4. Beijing Healthcare Security Administration. Notice on Issuing the Management Measures for Excluding Payment for CHS-DRG Paid New Drugs and Technologies (Trial Implementation) (Jing YiBao Zhongxin Fa [2022] No. 30). Jul 13, 2022. [cited 24 March 2024]. Available from: https://ybj.beijing.gov.cn/tzgg2022/202207/t20220713_2798069.html
5. What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews